QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
NYSE:EBS

Emergent BioSolutions - EBS Stock Forecast, Price & News

$12.46
+0.08 (+0.65%)
(As of 12/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$12.30
▼
$12.87
50-Day Range
$11.61
▼
$21.45
52-Week Range
$11.34
▼
$52.28
Volume
887,771 shs
Average Volume
704,928 shs
Market Capitalization
$621.60 million
P/E Ratio
15.97
Dividend Yield
N/A
Price Target
$46.50

Emergent BioSolutions MarketRank™ Forecast

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
273.2% Upside
$46.50 Price Target
Short Interest
Bearish
6.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.37
Upright™ Environmental Score
News Sentiment
0.64mentions of Emergent BioSolutions in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$22,829 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.96) to $0.40 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.73 out of 5 stars

Medical Sector

58th out of 1,022 stocks

Pharmaceutical Preparations Industry

27th out of 499 stocks

See Top Rated MarketRank™ Stocks Here
EBS stock logo

About Emergent BioSolutions (NYSE:EBS) Stock

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Receive EBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter.

EBS Stock News Headlines

December 8, 2022 | finance.yahoo.com
Why Is Emergent Biosolutions (EBS) Down 3.7% Since Last Earnings Report?
December 7, 2022 | seekingalpha.com
Emergent BioSolutions: No Change To Thesis Following Latest Numbers, Recent Developments
December 6, 2022 | finance.yahoo.com
Emergent earns fast-track review for selling opioid overdose drug without prescription
December 6, 2022 | finance.yahoo.com
Narcan Maker Gets Fast-Tracked for Over-the-Counter Nasal Spray
December 6, 2022 | finance.yahoo.com
Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray
December 6, 2022 | finance.yahoo.com
FDA to review Emergent's request to approve over-the-counter Narcan
December 1, 2022 | finance.yahoo.com
Zacks.com featured highlights include Emergent Biosolutions, Western Digital, Thoughtworks Holding and DASAN Zhone Solutions.
December 1, 2022 | americanbankingnews.com
Emergent BioSolutions Inc. (NYSE:EBS) Director Sells $22,829.28 in Stock
December 1, 2022 | americanbankingnews.com
Emergent BioSolutions Inc. (NYSE:EBS) Receives $36.75 Average Price Target from Brokerages
November 14, 2022 | finance.yahoo.com
Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach
November 10, 2022 | finance.yahoo.com
Emergent BioSolutions lowers revenue guidance amid uncertainty over government's vaccine purchases
November 9, 2022 | finance.yahoo.com
Emergent's (EBS) Q3 Earnings and Revenues Miss Estimates
November 9, 2022 | seekingalpha.com
Emergent BioSolutions Inc. (EBS) Q3 2022 Earnings Call Transcript
November 9, 2022 | finance.yahoo.com
Emergent BioSolutions (EBS) Q3 2022 Earnings Call Transcript
November 8, 2022 | finance.yahoo.com
Emergent BioSolutions Reports Financial Results For Third Quarter 2022
November 7, 2022 | bizjournals.com
Durham drugmaker Chimerix eyes potential roadmap to profitability after $238M deal
November 4, 2022 | finance.yahoo.com
Durham drugmaker eyes potential roadmap to profitability after $238M deal
November 1, 2022 | finance.yahoo.com
Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines
November 1, 2022 | msn.com
Emergent Biosolutions (EBS) Expected to Beat Earnings Estimates: Should You Buy?
October 18, 2022 | finance.yahoo.com
Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022
September 27, 2022 | finance.yahoo.com
Durham pharma nets $238M for smallpox drug with more payouts lined up
September 26, 2022 | finance.yahoo.com
Chimerix Announces Closing of TEMBEXA Sale to Emergent BioSolutions
September 26, 2022 | finance.yahoo.com
Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
September 6, 2022 | finance.yahoo.com
Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate
September 2, 2022 | nasdaq.com
Emergent Biosolutions Inc Shares Near 52-Week Low - Market Mover
See More Headlines
Receive EBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter.

EBS Company Calendar

Last Earnings
11/08/2022
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NYSE:EBS
CUSIP
29089Q10
CIK
1367644
Web
www.emergentbiosolutions.com
Phone
(240) 631-3200
Fax
301-795-1899
Employees
2,416
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$46.50
High Stock Price Forecast
$77.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+273.2%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$0.78
Trailing P/E Ratio
15.97
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$230.90 million
Net Margins
3.54%
Pretax Margin
7.73%
Return on Equity
9.52%
Return on Assets
5.15%

Debt

Debt-to-Equity Ratio
0.71
Current Ratio
4.17
Quick Ratio
2.13

Sales & Book Value

Annual Sales
$1.79 billion
Price / Sales
0.35
Cash Flow
$8.59 per share
Price / Cash Flow
1.45
Book Value
$30.09 per share
Price / Book
0.41

Miscellaneous

Outstanding Shares
49,888,000
Free Float
44,350,000
Market Cap
$621.60 million
Optionable
Optionable
Beta
0.91

Key Executives

  • Mr. Robert G. Kramer Sr. (Age 65)
    CEO, Pres & Exec. Director
    Comp: $1.93M
  • Mr. Richard S. LindahlMr. Richard S. Lindahl (Age 58)
    Exec. VP, CFO & Treasurer
    Comp: $858.61k
  • Mr. Adam R. Havey (Age 51)
    Exec. VP & COO
    Comp: $843.1k
  • Mr. Atul Saran (Age 49)
    Exec. VP & Chief Strategy and Devel. Officer
    Comp: $820.66k
  • Mr. Robert G. Burrows
    VP of Investor Relations
  • Ms. Jennifer L. Fox
    Exec. VP of External Affairs, Gen. Counsel & Corp. Sec.
  • Ms. Coleen Glessner
    Exec. VP of Global Quality and Ethics & Compliance
  • Ms. Lynn Kieffer
    VP of Corp. Communications
  • Ms. Katherine Strei (Age 60)
    Exec. VP of HR & Chief HR Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













EBS Stock - Frequently Asked Questions

Should I buy or sell Emergent BioSolutions stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last year. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" EBS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EBS, but not buy additional shares or sell existing shares.
View EBS analyst ratings or view top-rated stocks.

What is Emergent BioSolutions' stock price forecast for 2023?

6 brokers have issued twelve-month target prices for Emergent BioSolutions' stock. Their EBS share price forecasts range from $25.00 to $77.00. On average, they expect the company's stock price to reach $46.50 in the next year. This suggests a possible upside of 265.0% from the stock's current price.
View analysts price targets for EBS or view top-rated stocks among Wall Street analysts.

How have EBS shares performed in 2022?

Emergent BioSolutions' stock was trading at $43.47 on January 1st, 2022. Since then, EBS shares have decreased by 70.7% and is now trading at $12.74.
View the best growth stocks for 2022 here.

Are investors shorting Emergent BioSolutions?

Emergent BioSolutions saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 2,570,000 shares, an increase of 19.0% from the October 31st total of 2,160,000 shares. Based on an average daily volume of 749,300 shares, the short-interest ratio is presently 3.4 days. Approximately 6.3% of the shares of the company are sold short.
View Emergent BioSolutions' Short Interest.

When is Emergent BioSolutions' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our EBS earnings forecast.

How were Emergent BioSolutions' earnings last quarter?

Emergent BioSolutions Inc. (NYSE:EBS) posted its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.35 by $2.71. The biopharmaceutical company earned $329 million during the quarter, compared to the consensus estimate of $484.77 million. Emergent BioSolutions had a net margin of 3.54% and a trailing twelve-month return on equity of 9.52%. Emergent BioSolutions's revenue for the quarter was down 14.6% compared to the same quarter last year. During the same period in the prior year, the company earned $2.19 earnings per share.

What guidance has Emergent BioSolutions issued on next quarter's earnings?

Emergent BioSolutions updated its FY 2022 earnings guidance on Thursday, December, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.05 billion-$1.10 billion, compared to the consensus revenue estimate of $1.20 billion.

What is Bob Kramer's approval rating as Emergent BioSolutions' CEO?

38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Emergent BioSolutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), Salesforce (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Block (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV).

What is Emergent BioSolutions' stock symbol?

Emergent BioSolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

Who are Emergent BioSolutions' major shareholders?

Emergent BioSolutions' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (16.83%), Vanguard Group Inc. (10.41%), State Street Corp (8.65%), Dimensional Fund Advisors LP (3.86%), Jacobs Levy Equity Management Inc. (1.94%) and Neuberger Berman Group LLC (1.38%). Insiders that own company stock include Adam Havey, Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Louis W Sullivan, Richard S Lindahl, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi.
View institutional ownership trends.

How do I buy shares of Emergent BioSolutions?

Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Emergent BioSolutions' stock price today?

One share of EBS stock can currently be purchased for approximately $12.74.

How much money does Emergent BioSolutions make?

Emergent BioSolutions (NYSE:EBS) has a market capitalization of $635.60 million and generates $1.79 billion in revenue each year. The biopharmaceutical company earns $230.90 million in net income (profit) each year or $0.78 on an earnings per share basis.

How many employees does Emergent BioSolutions have?

The company employs 2,416 workers across the globe.

How can I contact Emergent BioSolutions?

Emergent BioSolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The official website for the company is www.emergentbiosolutions.com. The biopharmaceutical company can be reached via phone at (240) 631-3200, via email at burrowsr@ebsi.com, or via fax at 301-795-1899.

This page (NYSE:EBS) was last updated on 12/8/2022 by MarketBeat.com Staff